{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:35:25Z","timestamp":1794105325619,"version":"4.8.0"},"reference-count":244,"publisher":"Bentham Science Publishers Ltd.","issue":"25","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,10,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Adenosine is a purine nucleoside, responsible for the regulation of a wide range of physiological and pathophysiological conditions by binding with four G-protein-coupled receptors (GPCRs), namely A1, A2A, A2B and A3 adenosine receptors (ARs). In particular, A1 AR is ubiquitously present, mediating a variety of physiological processes throughout the body, thus represents a promising drug target for the management of various pathological conditions. Agonists of A1 AR are found to be useful for the treatment of atrial arrhythmia, angina, type-2 diabetes, glaucoma, neuropathic pain, epilepsy, depression and Huntington\u2019s disease, whereas antagonists are being investigated for the treatment of diuresis, congestive heart failure, asthma, COPD, anxiety and dementia. However, treatment with full A1 AR agonists has been associated with numerous challenges like cardiovascular side effects, off-target activation as well as desensitization of A1 AR leading to tachyphylaxis. In this regard, partial agonists of A1 AR have been found to be beneficial in enhancing insulin sensitivity and subsequently reducing blood glucose level, while avoiding severe CVS side effects and tachyphylaxis. Allosteric enhancer of A1 AR is found to be potent for the treatment of neuropathic pain, culminating the side effects related to off-target tissue activation of A1 AR. This review provides an overview of the medicinal chemistry and therapeutic potential of various agonists\/partial agonists, antagonists and allosteric modulators of A1 AR, with a particular emphasis on their current status and future perspectives in clinical settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1381612825666190716100509","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T05:00:57Z","timestamp":1563858057000},"page":"2697-2715","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-2874","authenticated-orcid":true,"given":"Pran Kishore","family":"Deb","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Philadelphia University, PO Box - 1, 19392, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyendra","family":"Deka","sequence":"additional","affiliation":[{"name":"Pratiksha Institute of Pharmaceutical Sciences, Chandrapur Road, Panikhaiti, Guwahati-26, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pobitra","family":"Borah","sequence":"additional","affiliation":[{"name":"Pratiksha Institute of Pharmaceutical Sciences, Chandrapur Road, Panikhaiti, Guwahati-26, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara N.","family":"Abed","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Philadelphia University, PO Box - 1, 19392, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Norbert","family":"Klotz","sequence":"additional","affiliation":[{"name":"University of W\u00fcrzburg, Department of Pharmacology and Toxicology Versbacher Str. 9, D-97078 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-90808-3","author":"Borea P.A.","year":"2018","unstructured":"Borea P.A.; Varani K.; Gessi S.; Merighi S.; Vincenzi F.; The Adenosine Receptors 2018","journal-title":"The Adenosine Receptors"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","volume":"98","author":"Borea P.A.","year":"2018","unstructured":"Borea P.A.; Gessi S.; Merighi S.; Vincenzi F.; Varani K.; Pharmacology of adenosine receptors: the state of the art. Physiol Rev 2018,98(3),1591-1625","journal-title":"Physiol Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00109-013-1101-6","volume":"92","author":"Fredholm B.B.","year":"2014","unstructured":"Fredholm B.B.; Adenosine-a physiological or pathophysiological agent? J Mol Med (Berl) 2014,92(3),201-206","journal-title":"J Mol Med (Berl)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-12-385526-8.00002-3","volume":"61","author":"Gessi S.","year":"2011","unstructured":"Gessi S.; Merighi S.; Varani K.; Borea P.A.; Adenosine receptors in health and disease. Adv Pharmacol 2011,61,41-75","journal-title":"Adv Pharmacol"},{"key":"ref=5","first-page":"527","volume":"53","author":"Fredholm B.B.","year":"2001","unstructured":"Fredholm B.B.; IJzerman A.P.; Jacobson K.A.; Klotz K-N.; Linden J.; International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001,53(4),527-552","journal-title":"Pharmacol Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.110.003285","volume":"63","author":"Fredholm B.B.","year":"2011","unstructured":"Fredholm B.B.; IJzerman A.P.; Jacobson K.A.; Linden J.; M\u00fcller C.E.; International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 2011,63(1),1-34","journal-title":"Pharmacol Rev"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.tips.2016.02.006","volume":"37","author":"Borea P.A.","year":"2016","unstructured":"Borea P.A.; Gessi S.; Merighi S.; Varani K.; Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects? Trends Pharmacol Sci 2016,37(6),419-434","journal-title":"Trends Pharmacol Sci"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-319-90808-3_4","author":"Gao Z-G.","year":"2018","unstructured":"Gao Z-G.; Tosh D.K.; Jain S.; Yu J.; Suresh R.R.; Jacobson K.A.A.; A adenosine receptor agonists, antagonists, and allosteric modulators. ed, The Adenosine Receptors Springer 2018,59-89","journal-title":"ed, The Adenosine Receptors Springer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/5584_2017_61","author":"Varani K.","year":"2017","unstructured":"Varani K.; Vincenzi F.; Merighi S.; Gessi S.; Borea P.A.; Biochemical and pharmacological role of A adenosine receptors and their modulation as novel therapeutic strategy ed Protein Reviews Springer2017,193-232","journal-title":"ed Protein Reviews"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-319-90808-3_3","author":"Merighi S.","year":"2018","unstructured":"Merighi S.; Gessi S.; Borea P.A.; Adenosine Receptors: Structure, Distribution, and Signal Transduction. ed The Adenosine Receptors Springer2018,33-57","journal-title":"ed The Adenosine Receptors"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-540-89615-9_2","author":"Kiesman W.F.","year":"2009","unstructured":"Kiesman W.F.; Elzein E.; Zablocki J.; A1 adenosine receptor antagonists, agonists, and allosteric enhancers. ed Adenosine receptors in health and disease Springer2009,25-58","journal-title":"ed Adenosine receptors in health and disease"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s002100000313","volume":"362","author":"Fredholm B.B.","year":"2000","unstructured":"Fredholm B.B.; Arslan G.; Halldner L.; Kull B.; Schulte G.; Wasserman W.; Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 2000,362(4-5),364-374","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=13","first-page":"255","volume":"9","author":"Ellis M.J.","year":"1995","unstructured":"Ellis M.J.; Lindon A.C.; Flint K.J.; Jones N.C.; Goodbourn S.; Activating transcription factor-1 is a specific antagonist of the cyclic adenosine 3\u2032.5\u2032-monophosphate (cAMP) response element-binding protein-1-mediated response to cAMP. Mol Endocrinol 1995,9(2),255-265","journal-title":"Mol Endocrinol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.1523\/JNEUROSCI.17-13-04956.1997","volume":"17","author":"Biber K.","year":"1997","unstructured":"Biber K.; Klotz K-N.; Berger M.; Gebicke-H\u00e4rter P.J.; van Calker D.; Adenosine A1 receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression. J Neurosci 1997,17(13),4956-4964","journal-title":"J Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"7680","DOI":"10.1523\/JNEUROSCI.22-17-07680.2002","volume":"22","author":"Basheer R.","year":"2002","unstructured":"Basheer R.; Arrigoni E.; Thatte H.S.; Greene R.W.; Ambudkar I.S.; McCarley R.W.; Adenosine induces inositol 1,4,5-trisphosphate receptor-mediated mobilization of intracellular calcium stores in basal forebrain cholinergic neurons. J Neurosci 2002,22(17),7680-7686","journal-title":"J Neurosci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s12013-014-9992-6","volume":"70","author":"Nalli A.D.","year":"2014","unstructured":"Nalli A.D.; Kumar D.P.; Al-Shboul O.; Regulation of G\u03b2\u03b3i-dependent PLC-\u03b23 activity in smooth muscle: inhibitory phosphorylation of PLC-\u03b23 by PKA and PKG and stimulatory phosphorylation of G\u03b1i-GTPase-activating protein RGS2 by PKG. Cell Biochem Biophys 2014,70(2),867-880","journal-title":"Cell Biochem Biophys"},{"key":"ref=17","first-page":"H820","volume":"259","author":"Kirsch G.E.","year":"1990","unstructured":"Kirsch G.E.; Codina J.; Birnbaumer L.; Brown A.M.; Coupling of ATP-sensitive K+ channels to A1 receptors by G proteins in rat ventricular myocytes. Am J Physiol 1990,259(3 Pt 2),H820-H826","journal-title":"Am J Physiol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1124\/mol.58.3.477","volume":"58","author":"Schulte G.","year":"2000","unstructured":"Schulte G.; Fredholm B.B.; Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1\/2. Mol Pharmacol 2000,58(3),477-482","journal-title":"Mol Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0898-6568(03)00058-5","volume":"15","author":"Schulte G.","year":"2003","unstructured":"Schulte G.; Fredholm B.B.; Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 2003,15(9),813-827","journal-title":"Cell Signal"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1002\/phy2.37","volume":"1","author":"Kunduri S.","year":"2013","unstructured":"Kunduri S.; Dick G.; Nayeem M.; Mustafa S.; Adenosine A receptor signaling inhibits BK channels through a PKC\u03b1-dependent mechanism in mouse aortic smooth muscle. Physiol Rep 2013,1(3)","journal-title":"Physiol Rep"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0898-6568(01)00235-2","volume":"14","author":"Klinger M.","year":"2002","unstructured":"Klinger M.; Freissmuth M.; Nanoff C.; Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal 2002,14(2),99-108","journal-title":"Cell Signal"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tips.2017.11.001","volume":"39","author":"Jespers W.","year":"2018","unstructured":"Jespers W.; Schiedel A.C.; Heitman L.H.; Structural mapping of adenosine receptor mutations: ligand binding and signaling mechanisms. Trends Pharmacol Sci 2018,39(1),75-89","journal-title":"Trends Pharmacol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/mol.116.105007","volume":"90","author":"Nguyen A.T.","year":"2016","unstructured":"Nguyen A.T.; Baltos J-A.; Thomas T.; Extracellular loop 2 of the adenosine A1 receptor has a key role in orthosteric ligand affinity and agonist efficacy. Mol Pharmacol 2016,90(6),703-714","journal-title":"Mol Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.cell.2017.01.042","volume":"168","author":"Glukhova A.","year":"2017","unstructured":"Glukhova A.; Thal D.M.; Nguyen A.T.; Structure of the adenosine A1 receptor reveals the basis for subtype selectivity. Cell 2017,168,867-877","journal-title":"Cell"},{"key":"ref=25","author":"Christopoulos A.","year":"2004","unstructured":"Christopoulos A.; May L.; Avlani V.; Sexton P.; G-protein-coupled receptor allosterism: the promise and the problem (s). 2004"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1124\/pr.54.2.323","volume":"54","author":"Christopoulos A.","year":"2002","unstructured":"Christopoulos A.; Kenakin T.; G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002,54(2),323-374","journal-title":"Pharmacol Rev"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1124\/mol.113.088682","volume":"85","author":"Kennedy D.P.","year":"2014","unstructured":"Kennedy D.P.; McRobb F.M.; Leonhardt S.A.; The second extracellular loop of the adenosine A1 receptor mediates activity of allosteric enhancers. Mol Pharmacol 2014,85(2),301-309","journal-title":"Mol Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.4155\/fmc.15.65","volume":"7","author":"Romagnoli R.","year":"2015","unstructured":"Romagnoli R.; Baraldi P.G.; Moorman A.R.; Borea P.A.; Varani K.; Current status of A1 adenosine receptor allosteric enhancers. Future Med Chem 2015,7(10),1247-1259","journal-title":"Future Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1021\/acs.jcim.7b00455","volume":"58","author":"Lagarias P.","year":"2018","unstructured":"Lagarias P.; Vrontaki E.; Lambrinidis G.; Discovery of novel adenosine receptor antagonists through a combined structure- and ligand-based approach followed by molecular dynamics investigation of ligand binding mode. J Chem Inf Model 2018,58(4),794-815","journal-title":"J Chem Inf Model"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s10822-012-9612-8","volume":"26","author":"Sirci F.","year":"2012","unstructured":"Sirci F.; Goracci L.; Rodr\u00edguez D.; van Muijlwijk-Koezen J.; Guti\u00e9rrez-de-Ter\u00e1n H.; Mannhold R.; Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A(1), A (2A), A (2B), and A (3) receptor antagonists. J Comput Aided Mol Des 2012,26(11),1247-1266","journal-title":"J Comput Aided Mol Des"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.bmcl.2010.11.094","volume":"21","author":"Pran Kishore D.","year":"2011","unstructured":"Pran Kishore D.; Balakumar C.; Raghuram Rao A.; Roy P.P.; Roy K.; QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype. Bioorg Med Chem Lett 2011,21(2),818-823","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/med.20108","volume":"28","author":"Gonz\u00e1lez M.P.","year":"2008","unstructured":"Gonz\u00e1lez M.P.; Ter\u00e1n C.; Teijeira M.; Search for new antagonist ligands for adenosine receptors from QSAR point of view. How close are we? Med Res Rev 2008,28(3),329-371","journal-title":"Med Res Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/1568026616666160719164207","volume":"17","author":"Guti\u00e9rrez-de-Ter\u00e1n H.","year":"2017","unstructured":"Guti\u00e9rrez-de-Ter\u00e1n H.; Sallander J.; Sotelo E.; Structure-based rational design of adenosine receptor ligands. Curr Top Med Chem 2017,17(1),40-58","journal-title":"Curr Top Med Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1021\/bi200100t","volume":"50","author":"Rodr\u00edguez D.","year":"2011","unstructured":"Rodr\u00edguez D.; Pi\u00f1eiro \u00c1.; Guti\u00e9rrez-de-Ter\u00e1n H.; Molecular dynamics simulations reveal insights into key structural elements of adenosine receptors. Biochemistry 2011,50(19),4194-4208","journal-title":"Biochemistry"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/cbdd.13155","volume":"91","author":"Deb P.K.","year":"2018","unstructured":"Deb P.K.; Mailavaram R.; Chandrasekaran B.; Synthesis, adenosine receptor binding and molecular modelling studies of novel thieno[2,3-d]pyrimidine derivatives. Chem Biol Drug Des 2018,91(4),962-969","journal-title":"Chem Biol Drug Des"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"750","DOI":"10.2174\/1381612825666190304123545","volume":"25","author":"Samanta P.N.","year":"2019","unstructured":"Samanta P.N.; Kar S.; Leszczynski J.; Recent advances of in-silico modeling of potent antagonists for the adenosine receptors. Curr Pharm Des 2019,25(7),750-773","journal-title":"Curr Pharm Des"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2174\/1381612825666190304123414","volume":"25","author":"Al-Shar\u2019i N.A.","year":"2019","unstructured":"Al-Shar\u2019i N.A.; Al-Balas Q.A.; Molecular dynamics simulations of adenosine receptors: Advances, applications and trends. Curr Pharm Des 2019,25(7),783-816","journal-title":"Curr Pharm Des"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2174\/1381612825666190304122624","volume":"25","author":"Mahmod Al-Qattan M.N.","year":"2019","unstructured":"Mahmod Al-Qattan M.N.; Mordi M.N.; Molecular basis of modulating adenosine receptors activities. Curr Pharm Des 2019,25(7),817-831","journal-title":"Curr Pharm Des"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"774","DOI":"10.2174\/1381612825666190306162006","volume":"25","author":"Agrawal N.","year":"2019","unstructured":"Agrawal N.; Chandrasekaran B.; Al-Aboudi A.; Recent advances in the in-silico structure-based and ligand-based approaches for the design and discovery of agonists and antagonists of A2A adenosine receptor. Curr Pharm Des 2019,25(7),774-782","journal-title":"Curr Pharm Des"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2174\/1381612825999190515120510","volume":"25","author":"Deb P.","year":"2019","unstructured":"Deb P.; Recent updates in the computer aided drug design strategies for the discovery of agonists and antagonists of adenosine receptors. 2019,25(7),747-749"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"30045","DOI":"10.1016\/j.drudis.2019.05.011","volume":"S1359-6446","author":"Deb PK","year":"2019","unstructured":"Deb PK; Chandrasekaran B; Mailavaram R; Tekade RK; Jaber AMY; Molecular modeling approaches for the discovery of adenosine A2B receptor antagonists: current status and future perspectives. Drug Discov Today 2019,S1359-6446(19),30045-5","journal-title":"Drug Discov Today"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1111\/cbdd.13528","volume":"94","author":"Shaik K.","year":"2019","unstructured":"Shaik K.; Deb P.K.; Mailavaram R.P.; Chandrasekaran B.; Kachler S.; Klotz K.N.; Yousef Jaber Am. 7-Amino-2-aryl\/heteroaryl-5-oxo-5, 8-dihydro [1, 2, 4] triazolo [1, 5-a] pyridine-6-carbonitriles: Synthesis and Adenosine Receptor Binding Studies. Chem Biol Drug Des 2019,94(2),1568-1573","journal-title":"Chem Biol Drug Des"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/s00044-017-2099-z","volume":"27","author":"Chandrasekaran B.","year":"2018","unstructured":"Chandrasekaran B.; Deb P.K.; Kachler S.; Akkinepalli R.R.; Mailavaram R.; Klotz K-N.; Synthesis and adenosine receptors binding studies of new fluorinated analogues of pyrido [2, 3-d] pyrimidines and quinazolines. Med Chem Res 2018,27,756-767","journal-title":"Med Chem Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"878","DOI":"10.2174\/156802610791268729","volume":"10","author":"Schenone S.","year":"2010","unstructured":"Schenone S.; Brullo C.; Musumeci F.; Bruno O.; Botta M.; A1 receptors ligands: past, present and future trends. Curr Top Med Chem 2010,10(9),878-901","journal-title":"Curr Top Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1517\/13543780802497284","volume":"17","author":"Elzein E.","year":"2008","unstructured":"Elzein E.; Zablocki J.; A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 2008,17(12),1901-1910","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1096\/fasebj.9.5.7896004","volume":"9","author":"Belardinelli L.","year":"1995","unstructured":"Belardinelli L.; Shryock J.C.; Song Y.; Wang D.; Srinivas M.; Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J 1995,9(5),359-365","journal-title":"FASEB J"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/hrt.63.1.3","volume":"63","author":"Belardinelli L.","year":"1990","unstructured":"Belardinelli L.; Lerman B.B.; Electrophysiological basis for the use of adenosine in the diagnosis and treatment of cardiac arrhythmias. Br Heart J 1990,63(1),3-4","journal-title":"Br Heart J"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1517\/14728214.8.2.537","volume":"8","author":"Yan L.","year":"2003","unstructured":"Yan L.; Burbiel J.C.; Maass A.; M\u00fcller C.E.; Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 2003,8(2),537-576","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/14728214.12.3.479","volume":"12","author":"Gao Z-G.","year":"2007","unstructured":"Gao Z-G.; Jacobson K.A.; Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 2007,12(3),479-492","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1517\/14728214.2011.644786","volume":"16","author":"Gao Z-G.","year":"2011","unstructured":"Gao Z-G.; Jacobson K.A.; Emerging adenosine receptor agonists\u2013an update. Expert Opin Emerg Drugs 2011,16(4),597-602","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s002100000315","volume":"362","author":"Klotz K-N.","year":"2000","unstructured":"Klotz K-N.; Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol 2000,362(4-5),382-391","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.2174\/0929867003374101","volume":"7","author":"Muller C.E.","year":"2000","unstructured":"Muller C.E.; Adenosine receptor ligands-recent developments part I. Agonists. Curr Med Chem 2000,7(12),1269-1288","journal-title":"Curr Med Chem"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.bbamem.2010.12.017","volume":"1808","author":"M\u00fcller C.E.","year":"2011","unstructured":"M\u00fcller C.E.; Jacobson K.A.; Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 2011,1808(5),1290-1308","journal-title":"Biochim Biophys Acta"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrd1983","volume":"5","author":"Jacobson K.A.","year":"2006","unstructured":"Jacobson K.A.; Gao Z-G.; Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006,5(3),247-264","journal-title":"Nat Rev Drug Discov"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0079-6468(08)00204-X","volume":"47","author":"Nell P.G.","year":"2009","unstructured":"Nell P.G.; Albrecht-K\u00fcpper B.; The adenosine A1 receptor and its ligands. Prog Med Chem 2009,47,163-201","journal-title":"Prog Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/164_2016_83","volume":"243","author":"Dinh W.","year":"2017","unstructured":"Dinh W.; Albrecht-K\u00fcpper B.; Gheorghiade M.; Voors A.A.; van der Laan M.; Sabbah H.N.; Partial adenosine A1 agonist in heart failure. Handb Exp Pharmacol 2017,243,177-203","journal-title":"Handb Exp Pharmacol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.2174\/15680266106061375","volume":"6","author":"Akkari R.","year":"2006","unstructured":"Akkari R.; Burbiel J.C.; Hockemeyer J.; M\u00fcller C.E.; Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr Top Med Chem 2006,6(13),1375-1399","journal-title":"Curr Top Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1517\/13543776.12.4.489","volume":"12","author":"Jacobson M.A.","year":"2002","unstructured":"Jacobson M.A.; Adenosine receptor agonists. Expert Opin Ther Pat 2002,12,489-501","journal-title":"Expert Opin Ther Pat"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/cs0860593","volume":"86","author":"Thompson C.S.","year":"1994","unstructured":"Thompson C.S.; Strong P.; Mikhailidis D.P.; Improvement of ketoacidosis in the diabetic rat after the administration of the oral antilipolytic agent GR 79236. Clin Sci (Lond) 1994,86(5),593-598","journal-title":"Clin Sci (Lond)"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/bja\/aem075","volume":"98","author":"Sneyd J.R.","year":"2007","unstructured":"Sneyd J.R.; Langton J.A.; Allan L.G.; Peacock J.E.; Rowbotham D.J.; Multicentre evaluation of the adenosine agonist GR79236X in patients with dental pain after third molar extraction. Br J Anaesth 2007,98(5),672-676","journal-title":"Br J Anaesth"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ddr.430340305","volume":"34","author":"Wagner H.","year":"1995","unstructured":"Wagner H.; Milavec-Krizman M.; Gadient F.; General pharmacology of SDZ WAG 994, a potent selective and orally active adenosine A1 receptor agonist. Drug Dev Res 1995,34,276-288","journal-title":"Drug Dev Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0968-0896(01)00384-4","volume":"10","author":"Hutchinson S.A.","year":"2002","unstructured":"Hutchinson S.A.; Baker S.P.; Scammells P.J.; New 2,N6-disubstituted adenosines: potent and selective A1 adenosine receptor agonists. Bioorg Med Chem 2002,10(4),1115-1122","journal-title":"Bioorg Med Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1016\/j.bmc.2004.07.004","volume":"12","author":"Hutchinson S.A.","year":"2004","unstructured":"Hutchinson S.A.; Baker S.P.; Linden J.; Scammells P.J.; New potent and selective A1 adenosine receptor agonists. Bioorg Med Chem 2004,12(18),4877-4884","journal-title":"Bioorg Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1021\/jm960682u","volume":"42","author":"Knutsen L.J.","year":"1999","unstructured":"Knutsen L.J.; Lau J.; Petersen H.; N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. J Med Chem 1999,42(18),3463-3477","journal-title":"J Med Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/europace\/eut251","volume":"16","author":"Corino V.D.","year":"2014","unstructured":"Corino V.D.; Holmqvist F.; Mainardi L.T.; Platonov P.G.; Beta-blockade and A1-adenosine receptor agonist effects on atrial fibrillatory rate and atrioventricular conduction in patients with atrial fibrillation. Europace 2014,16(4),587-594","journal-title":"Europace"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/(SICI)1098-2299(199710)42:2<86:AID-DDR5>3.0.CO;2-L","volume":"42","author":"Thomsen C.","year":"1997","unstructured":"Thomsen C.; Valsborg J.S.; Foged C.; Knutsen L.; Characterization of [3H]-N-[R-(2-Benzothiazolyl) thio-2-propyl]-2-chloroadenosine ([3H]-NNC 21-0136) binding to rat brain: Profile of a novel selective agonist for adenosine A1 receptors. Drug Dev Res 1997,42,86-97","journal-title":"Drug Dev Res"},{"key":"ref=67","author":"Abracchio M.P.","year":"2013","unstructured":"Abracchio M.P.; Williams M.; Purinergic and Pyrimidinergic Signalling: Molecular, Nervous and Urogenitary System Function 2013","journal-title":"Purinergic and Pyrimidinergic Signalling: Molecular, Nervous and Urogenitary System Function"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1016\/S0960-894X(01)80737-X","volume":"3","author":"Knutsen L.J.","year":"1993","unstructured":"Knutsen L.J.; Lau J.; Sheardown M.J.; Thomsen C.; The synthesis and biochemical evaluation of new A1 selective adenosine receptor agonists containing 6-hydrazinopurine moieties. Bioorg Med Chem Lett 1993,3,2661-2666","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1016\/S0960-894X(97)10177-9","volume":"7","author":"Ha S.B.","year":"1997","unstructured":"Ha S.B.; Melman N.; Jacobson K.A.; Nair V.; New base-altered adenosine analogues: synthesis and affinity at adenosine A and A receptors. Bioorg Med Chem Lett 1997,7(24),3085-3090","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1021\/jm021074j","volume":"46","author":"Beukers M.W.","year":"2003","unstructured":"Beukers M.W.; Wanner M.J.; Von Frijtag Drabbe K\u00fcnzel J.K.; Klaasse E.C.; IJzerman A.P.; Koomen G-J.N.; N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. J Med Chem 2003,46(8),1492-1503","journal-title":"J Med Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejphar.2004.01.034","volume":"487","author":"Wittendorp M.C.","year":"2004","unstructured":"Wittendorp M.C.; von Frijtag Drabbe K\u00fcnzel J.; Ijzerman A.P.; Boddeke H.W.; Biber K.; The mouse brain adenosine A1 receptor: functional expression and pharmacology. Eur J Pharmacol 2004,487(1-3),73-79","journal-title":"Eur J Pharmacol"},{"key":"ref=72","first-page":"187","volume":"33","author":"Ehlert F.J.","year":"1988","unstructured":"Ehlert F.J.; Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 1988,33(2),187-194","journal-title":"Mol Pharmacol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1021\/jm970508l","volume":"41","author":"van der Wenden E.M.","year":"1998","unstructured":"van der Wenden E.M.; Carnielli M.; Roelen H.C.; Lorenzen A.; von Frijtag Drabbe K\u00fcnzel J.K.; IJzerman A.P.; 5\u2032-substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor. J Med Chem 1998,41(1),102-108","journal-title":"J Med Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2174\/1568026043450998","volume":"4","author":"Zablocki J.A.","year":"2004","unstructured":"Zablocki J.A.; Wu L.; Shryock J.; Belardinelli L.; Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF). Curr Top Med Chem 2004,4(8),839-854","journal-title":"Curr Top Med Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1021\/jm300095s","volume":"55","author":"Tosh D.K.","year":"2012","unstructured":"Tosh D.K.; Phan K.; Gao Z-G.; Optimization of adenosine 5\u2032-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. J Med Chem 2012,55(9),4297-4308","journal-title":"J Med Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s00210-004-0999-1","volume":"370","author":"Saegusa N.","year":"2004","unstructured":"Saegusa N.; Sato T.; Ogura T.; Komuro I.; Nakaya H.; Inhibitory effects of AMP 579, a novel cardioprotective adenosine A1\/A2A receptor agonist, on native IKr and cloned HERG current. Naunyn Schmiedebergs Arch Pharmacol 2004,370(6),492-499","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1021\/jm300965a","volume":"55","author":"Tosh D.K.","year":"2012","unstructured":"Tosh D.K.; Paoletta S.; Deflorian F.; Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. J Med Chem 2012,55(18),8075-8090","journal-title":"J Med Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0014-827X(01)01005-9","volume":"56","author":"M\u00fcller C.E.","year":"2001","unstructured":"M\u00fcller C.E.; A1 adenosine receptors and their ligands: overview and recent developments. Farmaco 2001,56(1-2),77-80","journal-title":"Farmaco"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0029-1186271","volume":"58","author":"Veres G.","year":"2010","unstructured":"Veres G.; Radovits T.; Otila G.; Efficacy of the non-adenosine analogue A1 adenosine receptor agonist (BR-4935) on cardiovascular function after cardiopulmonary bypass. Thorac Cardiovasc Surg 2010,58(2),86-92","journal-title":"Thorac Cardiovasc Surg"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/cbdd.12801","volume":"88","author":"Cosimelli B.","year":"2016","unstructured":"Cosimelli B.; Greco G.; Laneri S.; 4-amino-6-alkyloxy-2-alkylthiopyrimidine derivatives as novel non-nucleoside agonists for the adenosine A receptor. Chem Biol Drug Des 2016,88(5),724-729","journal-title":"Chem Biol Drug Des"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1161\/hc0102.101392","volume":"105","author":"Song Y.","year":"2002","unstructured":"Song Y.; Wu L.; Shryock J.C.; Belardinelli L.; Selective attenuation of isoproterenol-stimulated arrhythmic activity by a partial agonist of adenosine A1 receptor. Circulation 2002,105(1),118-123","journal-title":"Circulation"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1385\/CT:3:1:71","volume":"3","author":"Hayes E.S.","year":"2003","unstructured":"Hayes E.S.; Adenosine receptors and cardiovascular disease: the adenosine-1 receptor (A1) and A1 selective ligands. Cardiovasc Toxicol 2003,3(1),71-88","journal-title":"Cardiovasc Toxicol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1161\/CIRCULATIONAHA.104.510982","volume":"111","author":"Ellenbogen K.A.","year":"2005","unstructured":"Ellenbogen K.A.; O\u2019Neill G.; Prystowsky E.N.; Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation 2005,111(24),3202-3208","journal-title":"Circulation"},{"key":"ref=84","author":"Bayes M.","year":"2003","unstructured":"Bayes M.; Rabasseda X.; Prous J.; Gateways to clinical trials. ed 2003","journal-title":"ed"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bcp.2017.03.014","volume":"135","author":"Baltos J-A.","year":"2017","unstructured":"Baltos J-A.; Vecchio E.A.; Harris M.A.; Capadenoson, a clinically trialed partial adenosine A receptor agonist, can stimulate adenosine A receptor biased agonism. Biochem Pharmacol 2017,135,79-89","journal-title":"Biochem Pharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bcp.2015.11.013","volume":"99","author":"Baltos J-A.","year":"2016","unstructured":"Baltos J-A.; Gregory K.J.; White P.J.; Sexton P.M.; Christopoulos A.; May L.T.; Quantification of adenosine A(1) receptor biased agonism: Implications for drug discovery. Biochem Pharmacol 2016,99,101-112","journal-title":"Biochem Pharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11302-011-9274-3","volume":"8","author":"Albrecht-K\u00fcpper B.E.","year":"2012","unstructured":"Albrecht-K\u00fcpper B.E.; Leineweber K.; Nell P.G.; Partial adenosine A1 receptor agonists for cardiovascular therapies. Purinergic Signal 2012,8(Suppl. 1),91-99","journal-title":"Purinergic Signal"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ejmech.2015.07.023","volume":"101","author":"Louvel J.","year":"2015","unstructured":"Louvel J.; Guo D.; Soethoudt M.; Structure-kinetics relationships of Capadenoson derivatives as adenosine A1 receptor agonists. Eur J Med Chem 2015,101,681-691","journal-title":"Eur J Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S0140-6736(18)31808-7","volume":"393","author":"Rossignol P.","year":"2019","unstructured":"Rossignol P.; Hernandez A.F.; Solomon S.D.; Zannad F.; Heart failure drug treatment. Lancet 2019,393(10175),1034-1044","journal-title":"Lancet"},{"key":"ref=90","first-page":"1","volume":"28","author":"Tamargo J.","year":"2018","unstructured":"Tamargo J.; Caballero R.; Delp\u00f3n E.; New drugs in preclinical and early stage clinical development in the treatment of heart failure. Expert Opin Investig Drugs 2018,28,1-21","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.0954-6820.1985.tb01650.x","volume":"217","author":"Fredholm B.B.","year":"1985","unstructured":"Fredholm B.B.; On the mechanism of action of theophylline and caffeine. Acta Med Scand 1985,217(2),149-153","journal-title":"Acta Med Scand"},{"key":"ref=92","first-page":"588","volume":"258","author":"Biaggioni I.","year":"1991","unstructured":"Biaggioni I.; Paul S.; Puckett A.; Arzubiaga C.; Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther 1991,258(2),588-593","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3233\/JAD-160569","volume":"55","author":"Mendiola-Precoma J.","year":"2017","unstructured":"Mendiola-Precoma J.; Padilla K.; Rodr\u00edguez-Cruz A.; Berumen L.C.; Miledi R.; Garc\u00eda-Alcocer G.; Theobromine-induced changes in A 1 Purinergic receptor gene expression and distribution in a rat brain Alzheimer\u2019s disease model. J Alzheimers Dis 2017,55(3),1273-1283","journal-title":"J Alzheimers Dis"},{"key":"ref=94","first-page":"107","volume":"35","author":"Villani F.","year":"1997","unstructured":"Villani F.; De Maria P.; Ronchi E.; Galimberti M.; Oral doxophylline in patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther 1997,35(3),107-111","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1021\/cr0682195","volume":"108","author":"Baraldi P.G.","year":"2008","unstructured":"Baraldi P.G.; Tabrizi M.A.; Gessi S.; Borea P.A.; Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem Rev 2008,108(1),238-263","journal-title":"Chem Rev"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ejphar.2014.07.012","volume":"740","author":"Wilson C.N.","year":"2014","unstructured":"Wilson C.N.; Vance C.O.; Lechner M.G.; Matuschak G.M.; Lechner A.J.; Adenosine A1 receptor antagonist, L-97-1, improves survival and protects the kidney in a rat model of cecal ligation and puncture induced sepsis. Eur J Pharmacol 2014,740,346-352","journal-title":"Eur J Pharmacol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/BF00165806","volume":"336","author":"Lohse M.J.","year":"1987","unstructured":"Lohse M.J.; Klotz K-N.; Lindenborn-Fotinos J.; Reddington M.; Schwabe U.; Olsson R.A.; 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1987,336(2),204-210","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/ki.2010.204","volume":"78","author":"Hocher B.","year":"2010","unstructured":"Hocher B.; Adenosine A1 receptor antagonists in clinical research and development. Kidney Int 2010,78(5),438-445","journal-title":"Kidney Int"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1517\/14728210902721230","volume":"14","author":"Sedghi Y.","year":"2009","unstructured":"Sedghi Y.; Gaddam K.K.; Ventura H.O.; Emerging diuretics for the treatment of heart failure. Expert Opin Emerg Drugs 2009,14(1),195-204","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-540-89615-9_1","volume":"143","author":"Jacobson K.A.","year":"2009","unstructured":"Jacobson K.A.; Introduction to adenosine receptors as therapeutic targets. Handb Exp Pharmacol 2009,143,1-24","journal-title":"Handb Exp Pharmacol"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.str.2017.06.012","volume":"25","author":"Cheng R.K.","year":"2017","unstructured":"Cheng R.K.; Segala E.; Robertson N.; Structures of human A1 and A2A adenosine receptors with xanthines reveal determinants of selectivity. Structure 2017,25(8),1275-1285","journal-title":"Structure"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1089\/neu.2017.5006","volume":"35","author":"Hayashi S.","year":"2018","unstructured":"Hayashi S.; Inaji M.; Nariai T.; Increased binding potential of brain adenosine A1 receptor in chronic stages of patients with diffuse axonal injury measured with [1-methyl-11C] 8-dicyclopropylmethyl-1-methyl-3-propylxanthine positron emission tomography imaging. J Neurotrauma 2018,35(1),25-31","journal-title":"J Neurotrauma"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1073\/pnas.1614677114","volume":"114","author":"Elmenhorst D.","year":"2017","unstructured":"Elmenhorst D.; Elmenhorst E-M.; Hennecke E.; Recovery sleep after extended wakefulness restores elevated A adenosine receptor availability in the human brain. Proc Natl Acad Sci USA 2017,114(16),4243-4248","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=104","doi-asserted-by":"publisher","DOI":"10.2174\/187152407780059259","author":"Ishiwata K","year":"2007","unstructured":"Ishiwata K; Kimura Y; de Vries J; Erik F; Elsinga PH; PET tracers for mapping adenosine receptors as probes for diagnosis of CNS disorders 2007","journal-title":"PET tracers for mapping adenosine receptors as probes for diagnosis of CNS disorders"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/med.20048","volume":"26","author":"Moro S.","year":"2006","unstructured":"Moro S.; Gao Z.G.; Jacobson K.A.; Spalluto G.; Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Res Rev 2006,26(2),131-159","journal-title":"Med Res Rev"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.bmc.2010.01.072","volume":"18","author":"Scheiff A.B.","year":"2010","unstructured":"Scheiff A.B.; Yerande S.G.; El-Tayeb A.; 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem 2010,18(6),2195-2203","journal-title":"Bioorg Med Chem"},{"key":"ref=107","first-page":"490","volume":"276","author":"Martin P.L.","year":"1996","unstructured":"Martin P.L.; Wysocki R.J.; Barrett R.J.; May J.M.; Linden J.; Characterization of 8-(N-methylisopropyl)amino-N6-(5\u2032-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. J Pharmacol Exp Ther 1996,276(2),490-499","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1517\/13543776.7.5.419","volume":"7","author":"M\u00fcller C.E.","year":"1997","unstructured":"M\u00fcller C.E.; A1-adenosine receptor antagonists. Expert Opin Ther Pat 1997,7,419-440","journal-title":"Expert Opin Ther Pat"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ejmech.2016.09.081","volume":"125","author":"Alachouzos G.","year":"2017","unstructured":"Alachouzos G.; Lenselink E.B.; Mulder-Krieger T.; de Vries H.; IJzerman A.P.; Louvel J.; Synthesis and evaluation of N-substituted 2-amino-4,5-diarylpyrimidines as selective adenosine A receptor antagonists. Eur J Med Chem 2017,125,586-602","journal-title":"Eur J Med Chem"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.nucmedbio.2005.06.008","volume":"32","author":"Matsuya T.","year":"2005","unstructured":"Matsuya T.; Takamatsu H.; Murakami Y.; Synthesis and evaluation of [11C]FR194921 as a nonxanthine-type PET tracer for adenosine A1 receptors in the brain. Nucl Med Biol 2005,32(8),837-844","journal-title":"Nucl Med Biol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.nucmedbio.2016.09.004","volume":"44","author":"Kreft S.","year":"2017","unstructured":"Kreft S.; Bier D.; Holschbach M.H.; Schulze A.; Coenen H.H.; New potent A adenosine receptor radioligands for positron emission tomography. Nucl Med Biol 2017,44,69-77","journal-title":"Nucl Med Biol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.2174\/092986711797535335","volume":"18","author":"Paul S.","year":"2011","unstructured":"Paul S.; Elsinga P.H.; Ishiwata K.; Dierckx R.A.; van Waarde A.; Adenosine A(1) receptors in the central nervous system: their functions in health and disease, and possible elucidation by PET imaging. Curr Med Chem 2011,18(31),4820-4835","journal-title":"Curr Med Chem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/01.RES.75.6.961","volume":"75","author":"Kollias-Baker C.","year":"1994","unstructured":"Kollias-Baker C.; Ruble J.; Dennis D.; Bruns R.F.; Linden J.; Belardinelli L.; Allosteric enhancer PD 81,723 acts by novel mechanism to potentiate cardiac actions of adenosine. Circ Res 1994,75(6),961-971","journal-title":"Circ Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1016\/j.bmcl.2011.04.080","volume":"21","author":"Aurelio L.","year":"2011","unstructured":"Aurelio L.; Christopoulos A.; Flynn B.L.; Scammells P.J.; Sexton P.M.; Valant C.; The synthesis and biological evaluation of 2-amino-4,5,6,7,8,9-hexahydrocycloocta[b]thiophenes as allosteric modulators of the A1 adenosine receptor. Bioorg Med Chem Lett 2011,21(12),3704-3707","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.ddtec.2012.08.005","volume":"10","author":"Kimatrai-Salvador M.","year":"2013","unstructured":"Kimatrai-Salvador M.; Baraldi P.G.; Romagnoli R.; Allosteric modulation of A1-adenosine receptor: a review. Drug Discov Today Technol 2013,10(2),e285-e296","journal-title":"Drug Discov Today Technol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.molmed.2010.12.006","volume":"17","author":"Zylka M.J.","year":"2011","unstructured":"Zylka M.J.; Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med 2011,17(4),188-196","journal-title":"Trends Mol Med"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.neuropharm.2014.01.028","volume":"81","author":"Vincenzi F.","year":"2014","unstructured":"Vincenzi F.; Targa M.; Romagnoli R.; TRR469, a potent A(1) adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice. Neuropharmacology 2014,81,6-14","journal-title":"Neuropharmacology"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/978-3-319-90808-3_16","volume":"34","author":"Salvemini D.","year":"2018","unstructured":"Salvemini D.; Doyle T.M.; Largent-Milnes T.M.; Vanderah T.W.; The adenosine-receptor axis in chronic pain. Receptors 2018,34,413-437","journal-title":"Receptors"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1111\/bph.14337","volume":"175","author":"Vecchio E.A.","year":"2018","unstructured":"Vecchio E.A.; Baltos J.A.; Nguyen A.T.N.; Christopoulos A.; White P.J.; May L.T.; New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism. Br J Pharmacol 2018,175(21),4036-4046","journal-title":"Br J Pharmacol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.tips.2012.10.003","volume":"34","author":"Lane J.R.","year":"2013","unstructured":"Lane J.R.; Sexton P.M.; Christopoulos A.; Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol Sci 2013,34(1),59-66","journal-title":"Trends Pharmacol Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/1440-1681.12616","volume":"43","author":"Chuo C.H.","year":"2016","unstructured":"Chuo C.H.; Devine S.M.; Scammells P.J.; VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model. Clin Exp Pharmacol Physiol 2016,43(10),976-982","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-3-540-89615-9_11","volume":"193","author":"Wilson C.N.","year":"2009","unstructured":"Wilson C.N.; Nadeem A.; Spina D.; Brown R.; Page C.P.; Mustafa S.J.; Adenosine receptors and asthma. Handb Exp Pharmacol 2009,193,329-362","journal-title":"Handb Exp Pharmacol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/CIRCRESAHA.116.309726","volume":"120","author":"Burnstock G.","year":"2017","unstructured":"Burnstock G.; Purinergic signaling in the cardiovascular system. Circ Res 2017,120(1),207-228","journal-title":"Circ Res"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2174\/1381612820666141029100346","volume":"21","author":"Szentmiklosi A.J.","year":"2015","unstructured":"Szentmiklosi A.J.; Galajda Z.; Cseppento \u00c1.; The Janus face of adenosine: antiarrhythmic and proarrhythmic actions. Curr Pharm Des 2015,21(8),965-976","journal-title":"Curr Pharm Des"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bcp.2016.03.016","volume":"107","author":"Vyas F.S.","year":"2016","unstructured":"Vyas F.S.; Hargreaves A.J.; Bonner P.L.; Boocock D.J.; Coveney C.; Dickenson J.M.; A1 adenosine receptor-induced phosphorylation and modulation of transglutaminase 2 activity in H9c2 cells: A role in cell survival. Biochem Pharmacol 2016,107,41-58","journal-title":"Biochem Pharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7326\/0003-4819-113-2-104","volume":"113","author":"DiMarco J.P.","year":"1990","unstructured":"DiMarco J.P.; Miles W.; Akhtar M.; Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. Ann Intern Med 1990,113(2),104-110","journal-title":"Ann Intern Med"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1161\/01.RES.78.4.697","volume":"78","author":"Wang D.","year":"1996","unstructured":"Wang D.; Shryock J.C.; Belardinelli L.; Cellular basis for the negative dromotropic effect of adenosine on rabbit single atrioventricular nodal cells. Circ Res 1996,78(4),697-706","journal-title":"Circ Res"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.hrthm.2004.10.032","volume":"2","author":"Belardinelli L.","year":"2005","unstructured":"Belardinelli L.; Shryock J.C.; Wu L.; Song Y.; Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm 2005,2(2)(Suppl.),S16-S22","journal-title":"Heart Rhythm"},{"key":"ref=129","author":"Aurora J","year":"2005","unstructured":"Aurora J; Gill M; Ong K; Pharmaceutical formulation for controlled release of selodenoson 2005","journal-title":"Pharmaceutical formulation for controlled release of selodenoson"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1161\/CIRCEP.109.884429","volume":"2","author":"Mason P.K.","year":"2009","unstructured":"Mason P.K.; DiMarco J.P.; New pharmacological agents for arrhythmias. Circ Arrhythm Electrophysiol 2009,2(5),588-597","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10741-015-9522-7","volume":"21","author":"Greene S.J.","year":"2016","unstructured":"Greene S.J.; Sabbah H.N.; Butler J.; Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Fail Rev 2016,21(1),95-102","journal-title":"Heart Fail Rev"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00392-012-0430-8","volume":"101","author":"Tendera M.","year":"2012","unstructured":"Tendera M.; Gaszewska-\u017burek E.; Parma Z.; The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clin Res Cardiol 2012,101(7),585-591","journal-title":"Clin Res Cardiol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jacc.2007.03.059","volume":"50","author":"Greenberg B.","year":"2007","unstructured":"Greenberg B.; Thomas I.; Banish D.; Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol 2007,50(7),600-606","journal-title":"J Am Coll Cardiol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cardfail.2008.08.010","volume":"14","author":"Cotter G.","year":"2008","unstructured":"Cotter G.; Dittrich H.C.; Weatherley B.D.; The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008,14(8),631-640","journal-title":"J Card Fail"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","volume":"363","author":"Massie B.M.","year":"2010","unstructured":"Massie B.M.; O\u2019Connor C.M.; Metra M.; Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010,363(15),1419-1428","journal-title":"N Engl J Med"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/11594680-000000000-00000","volume":"35","author":"Teerlink J.R.","year":"2012","unstructured":"Teerlink J.R.; Iragui V.J.; Mohr J.P.; The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf 2012,35(3),233-244","journal-title":"Drug Saf"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/jcph.828","volume":"57","author":"Voors A.A.","year":"2017","unstructured":"Voors A.A.; D\u00fcngen H.D.; Senni M.; Safety and tolerability of neladenoson bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure. J Clin Pharmacol 2017,57(4),440-451","journal-title":"J Clin Pharmacol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejheart.2008.01.010","volume":"10","author":"Vallon V.","year":"2008","unstructured":"Vallon V.; Miracle C.; Thomson S.; Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail 2008,10(2),176-187","journal-title":"Eur J Heart Fail"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/978-3-540-89615-9_15","author":"Vallon V.","year":"2009","unstructured":"Vallon V.; Osswald H.; Adenosine receptors and the kidney. Handb Exp Pharmacol 2009(193),443-470","journal-title":"Handb Exp Pharmacol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/apha.12413","volume":"213","author":"Welch W.J.","year":"2015","unstructured":"Welch W.J.; Adenosine, type 1 receptors: role in proximal tubule Na+ reabsorption. Acta Physiol (Oxf) 2015,213(1),242-248","journal-title":"Acta Physiol (Oxf)"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.kint.2016.08.029","volume":"91","author":"Menzies R.I.","year":"2017","unstructured":"Menzies R.I.; Tam F.W.; Unwin R.J.; Bailey M.A.; Purinergic signaling in kidney disease. Kidney Int 2017,91(2),315-323","journal-title":"Kidney Int"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1124\/jpet.104.080432","volume":"313","author":"Rieg T.","year":"2005","unstructured":"Rieg T.; Steigele H.; Schnermann J.; Richter K.; Osswald H.; Vallon V.; Requirement of intact adenosine A1 receptors for the diuretic and natriuretic action of the methylxanthines theophylline and caffeine. J Pharmacol Exp Ther 2005,313(1),403-409","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cardfail.2007.08.006","volume":"13","author":"Dittrich H.C.","year":"2007","unstructured":"Dittrich H.C.; Gupta D.K.; Hack T.C.; Dowling T.; Callahan J.; Thomson S.; The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 2007,13(8),609-617","journal-title":"J Card Fail"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.jacc.2007.07.019","volume":"50","author":"Givertz M.M.","year":"2007","unstructured":"Givertz M.M.; Massie B.M.; Fields T.K.; Pearson L.L.; Dittrich H.C.; The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007,50(16),1551-1560","journal-title":"J Am Coll Cardiol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1161\/CIRCHEARTFAILURE.115.002271","volume":"8","author":"Vaduganathan M.","year":"2015","unstructured":"Vaduganathan M.; Butler J.; Pitt B.; Gheorghiade M.; Contemporary drug development in heart failure: call for hemodynamically neutral therapies. Circ Heart Fail 2015,8(4),826-831","journal-title":"Circ Heart Fail"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1161\/CIRCHEARTFAILURE.112.000208","volume":"6","author":"Sabbah H.N.","year":"2013","unstructured":"Sabbah H.N.; Gupta R.C.; Kohli S.; Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail 2013,6(3),563-571","journal-title":"Circ Heart Fail"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/01.ASN.0000102474.68613.AE","volume":"15","author":"Lee H.T.","year":"2004","unstructured":"Lee H.T.; Gallos G.; Nasr S.H.; Emala C.W.; A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol 2004,15(1),102-111","journal-title":"J Am Soc Nephrol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/sj.ki.5002227","volume":"71","author":"Lee H.T.","year":"2007","unstructured":"Lee H.T.; Kim M.; Jan M.; Penn R.B.; Emala C.W.; Renal tubule necrosis and apoptosis modulation by A1 adenosine receptor expression. Kidney Int 2007,71(12),1249-1261","journal-title":"Kidney Int"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrneph.2014.180","volume":"11","author":"Jang H.R.","year":"2015","unstructured":"Jang H.R.; Rabb H.; Immune cells in experimental acute kidney injury. Nat Rev Nephrol 2015,11(2),88-101","journal-title":"Nat Rev Nephrol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"F298","DOI":"10.1152\/ajprenal.00185.2003","volume":"286","author":"Lee H.T.","year":"2004","unstructured":"Lee H.T.; Xu H.; Nasr S.H.; Schnermann J.; Emala C.W.; A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. Am J Physiol Renal Physiol 2004,286(2),F298-F306","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1681\/ASN.2013010114","volume":"24","author":"Kim J.Y.","year":"2013","unstructured":"Kim J.Y.; Kim M.; Ham A.; IL-11 is required for A1 adenosine receptor-mediated protection against ischemic AKI. J Am Soc Nephrol 2013,24(10),1558-1570","journal-title":"J Am Soc Nephrol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"F1847","DOI":"10.1152\/ajprenal.00336.2007","volume":"293","author":"Joo J.D.","year":"2007","unstructured":"Joo J.D.; Kim M.; Horst P.; Acute and delayed renal protection against renal ischemia and reperfusion injury with A1 adenosine receptors. Am J Physiol Renal Physiol 2007,293(6),F1847-F1857","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"F1216","DOI":"10.1152\/ajprenal.00220.2012","volume":"303","author":"Lee H.T.","year":"2012","unstructured":"Lee H.T.; Park S.W.; Kim M.; Interleukin-11 protects against renal ischemia and reperfusion injury. Am J Physiol Renal Physiol 2012,303(8),F1216-F1224","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s11255-018-1797-x","volume":"50","author":"Xiong B.","year":"2018","unstructured":"Xiong B.; Li M.; Xiang S.; Han L.; A1AR-mediated renal protection against ischemia\/reperfusion injury is dependent on HSP27 induction. Int Urol Nephrol 2018,50(7),1355-1363","journal-title":"Int Urol Nephrol"},{"key":"ref=155","first-page":"70","volume":"220","author":"Dunwiddie T.V.","year":"1982","unstructured":"Dunwiddie T.V.; Worth T.; Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J Pharmacol Exp Ther 1982,220(1),70-76","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1528-1157.1985.tb05684.x","volume":"26","author":"Dragunow M.","year":"1985","unstructured":"Dragunow M.; Goddard G.V.; Laverty R.; Is adenosine an endogenous anticonvulsant? Epilepsia 1985,26(5),480-487","journal-title":"Epilepsia"},{"key":"ref=157","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-319-90808-3_13","author":"Rombo D.M.","year":"2018","unstructured":"Rombo D.M.; Ribeiro J.A.; Sebasti\u00e3o A.M.; Role of Adenosine Receptors in Epileptic Seizures. ed The Adenosine Receptors Springer2018,309-350","journal-title":"ed The Adenosine Receptors"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.yebeh.2016.05.036","volume":"61","author":"Amorim B.O.","year":"2016","unstructured":"Amorim B.O.; Hamani C.; Ferreira E.; Effects of A1 receptor agonist\/antagonist on spontaneous seizures in pilocarpine-induced epileptic rats. Epilepsy Behav 2016,61,168-173","journal-title":"Epilepsy Behav"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/epi.13360","volume":"57","author":"Klaft Z.J.","year":"2016","unstructured":"Klaft Z.J.; Hollnagel J.O.; Salar S.; Adenosine A1 receptor-mediated suppression of carbamazepine-resistant seizure-like events in human neocortical slices. Epilepsia 2016,57(5),746-756","journal-title":"Epilepsia"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/0896-6273(94)90321-2","volume":"12","author":"Wu L-G.","year":"1994","unstructured":"Wu L-G.; Saggau P.; Adenosine inhibits evoked synaptic transmission primarily by reducing presynaptic calcium influx in area CA1 of hippocampus. Neuron 1994,12(5),1139-1148","journal-title":"Neuron"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1113\/jphysiol.2007.132613","volume":"582","author":"Gundlfinger A.","year":"2007","unstructured":"Gundlfinger A.; Bischofberger J.; Johenning F.W.; Torvinen M.; Schmitz D.; Breustedt J.; Adenosine modulates transmission at the hippocampal mossy fibre synapse via direct inhibition of presynaptic calcium channels. J Physiol 2007,582(Pt 1),263-277","journal-title":"J Physiol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.neuropharm.2015.08.007","volume":"99","author":"Lusardi T.A.","year":"2015","unstructured":"Lusardi T.A.; Akula K.K.; Coffman S.Q.; Ruskin D.N.; Masino S.A.; Boison D.; Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats. Neuropharmacology 2015,99,500-509","journal-title":"Neuropharmacology"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1172\/JCI57813","volume":"121","author":"Masino S.A.","year":"2011","unstructured":"Masino S.A.; Li T.; Theofilas P.; A ketogenic diet suppresses seizures in mice through adenosine A receptors. J Clin Invest 2011,121(7),2679-2683","journal-title":"J Clin Invest"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/sj.bjp.0706043","volume":"144","author":"Schindler C.W.","year":"2005","unstructured":"Schindler C.W.; Karcz-Kubicha M.; Thorndike E.B.; Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists. Br J Pharmacol 2005,144(5),642-650","journal-title":"Br J Pharmacol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0014-2999(95)00557-9","volume":"294","author":"Adami M.","year":"1995","unstructured":"Adami M.; Bertorelli R.; Ferri N.; Foddi M.C.; Ongini E.; Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur J Pharmacol 1995,294(2-3),383-389","journal-title":"Eur J Pharmacol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-94-007-4719-7_1","volume":"986","author":"Burnstock G.","year":"2013","unstructured":"Burnstock G.; Introduction to purinergic signalling in the brain. Adv Exp Med Biol 2013,986,1-12","journal-title":"Adv Exp Med Biol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/978-3-540-89615-9_17","author":"Stone T.W.","year":"2009","unstructured":"Stone T.W.; Ceruti S.; Abbracchio M.P.; Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009(193),535-587","journal-title":"Handb Exp Pharmacol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-3-319-90808-3_9","volume":"34","author":"Ferrante A.","year":"2018","unstructured":"Ferrante A.; De Simone R.; Ajmone-Cat M.A.; Minghetti L.; Popoli P.; Adenosine receptors and neuroinflammation. Receptors 2018,34,217-237","journal-title":"Receptors"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0306-4522(02)00479-7","volume":"115","author":"Flor\u00e1n B.","year":"2002","unstructured":"Flor\u00e1n B.; Barajas C.; Flor\u00e1n L.; Erlij D.; Aceves J.; Adenosine A1 receptors control dopamine D1-dependent [(3)H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat. Neuroscience 2002,115(3),743-751","journal-title":"Neuroscience"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00702-006-0566-7","volume":"114","author":"Franco R.","year":"2007","unstructured":"Franco R.; Lluis C.; Canela E.I.; Receptor-receptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. J Neural Transm (Vienna) 2007,114(1),93-104","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.bbamem.2010.12.001","volume":"1808","author":"Gomes C.V.","year":"2011","unstructured":"Gomes C.V.; Kaster M.P.; Tom\u00e9 A.R.; Agostinho P.M.; Cunha R.A.; Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta 2011,1808(5),1380-1399","journal-title":"Biochim Biophys Acta"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.expneurol.2014.08.022","volume":"261","author":"Mango D.","year":"2014","unstructured":"Mango D.; Bonito-Oliva A.; Ledonne A.; Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice. Exp Neurol 2014,261,733-743","journal-title":"Exp Neurol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/jnc.13724","volume":"139","author":"Cunha R.A.","year":"2016","unstructured":"Cunha R.A.; How does adenosine control neuronal dysfunction and neurodegeneration? J Neurochem 2016,139(6),1019-1055","journal-title":"J Neurochem"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/mds.26627","volume":"31","author":"Jaberi E.","year":"2016","unstructured":"Jaberi E.; Rohani M.; Shahidi G.A.; Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction. Mov Disord 2016,31(7),1004-1011","journal-title":"Mov Disord"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1001\/jama.283.20.2674","volume":"283","author":"Ross G.W.","year":"2000","unstructured":"Ross G.W.; Abbott R.D.; Petrovitch H.; Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000,283(20),2674-2679","journal-title":"JAMA"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/mds.25076","volume":"27","author":"Palacios N.","year":"2012","unstructured":"Palacios N.; Gao X.; McCullough M.L.; Caffeine and risk of Parkinson\u2019s disease in a large cohort of men and women. Mov Disord 2012,27(10),1276-1282","journal-title":"Mov Disord"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-3-319-90808-3_12","volume":"34","author":"Blum D.","year":"2018","unstructured":"Blum D.; Chern E.C.; Domenici M.R.; What Is the Role of Adenosine Tone and Adenosine Receptors in Huntington\u2019s Disease? Receptors 2018,34,281-308","journal-title":"Receptors"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/978-3-642-45106-5_14","author":"Zuccato C.","year":"2014","unstructured":"Zuccato C.; Cattaneo E.; Huntington\u2019s disease 2014,357-409","journal-title":"Huntington\u2019s disease"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.nbd.2014.08.013","volume":"71","author":"Ferrante A.","year":"2014","unstructured":"Ferrante A.; Martire A.; Pepponi R.; Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington\u2019s disease. Neurobiol Dis 2014,71,193-204","journal-title":"Neurobiol Dis"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"10982","DOI":"10.1523\/JNEUROSCI.23-34-10982.2003","volume":"23","author":"Alfinito P.D.","year":"2003","unstructured":"Alfinito P.D.; Wang S-P.; Manzino L.; Rijhsinghani S.; Zeevalk G.D.; Sonsalla P.K.; Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci 2003,23(34),10982-10987","journal-title":"J Neurosci"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"9122","DOI":"10.1523\/JNEUROSCI.22-20-09122.2002","volume":"22","author":"Blum D.","year":"2002","unstructured":"Blum D.; Gall D.; Galas M-C.; d\u2019Alcantara P.; Bantubungi K.; Schiffmann S.N.; The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J Neurosci 2002,22(20),9122-9133","journal-title":"J Neurosci"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"8550","DOI":"10.1158\/0008-5472.CAN-06-0365","volume":"66","author":"Synowitz M.","year":"2006","unstructured":"Synowitz M.; Glass R.; F\u00e4rber K.; A1 adenosine receptors in microglia control glioblastoma-host interaction. Cancer Res 2006,66(17),8550-8557","journal-title":"Cancer Res"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lfs.2014.01.083","volume":"101","author":"Rivera-Oliver M.","year":"2014","unstructured":"Rivera-Oliver M.; D\u00edaz-R\u00edos M.; Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. Life Sci 2014,101(1-2),1-9","journal-title":"Life Sci"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2015.10.031","volume":"338","author":"Sawynok J.","year":"2016","unstructured":"Sawynok J.; Adenosine receptor targets for pain. Neuroscience 2016,338,1-18","journal-title":"Neuroscience"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.pain.2007.01.013","volume":"131","author":"Maione S.","year":"2007","unstructured":"Maione S.; de Novellis V.; Cappellacci L.; The antinociceptive effect of 2-chloro-2\u2032-C-methyl-N6-cyclopentyladenosine (2\u2032-Me-CCPA), a highly selective adenosine A1 receptor agonist, in the rat. Pain 2007,131(3),281-292","journal-title":"Pain"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"9407","DOI":"10.1073\/pnas.161292398","volume":"98","author":"Johansson B.","year":"2001","unstructured":"Johansson B.; Halldner L.; Dunwiddie T.V.; Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 2001,98(16),9407-9412","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.2174\/092986710792927831","volume":"17","author":"Romagnoli R.","year":"2010","unstructured":"Romagnoli R.; Baraldi P.G.; Tabrizi M.A.; Gessi S.; Borea P.A.; Merighi S.; Allosteric enhancers of A1 adenosine receptors: state of the art and new horizons for drug development. Curr Med Chem 2010,17(30),3488-3502","journal-title":"Curr Med Chem"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2174\/1389557054023242","volume":"5","author":"Gao Z-G.","year":"2005","unstructured":"Gao Z-G.; Kim S-K.; Ijzerman A.P.; Jacobson K.A.; Allosteric modulation of the adenosine family of receptors. Mini Rev Med Chem 2005,5(6),545-553","journal-title":"Mini Rev Med Chem"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2174\/138955707780859459","volume":"7","author":"Baraldi P.G.","year":"2007","unstructured":"Baraldi P.G.; Iaconinoto M.A.; Moorman A.R.; Allosteric enhancers for A1 adenosine receptor. Mini Rev Med Chem 2007,7(6),559-569","journal-title":"Mini Rev Med Chem"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.neuropharm.2016.09.015","volume":"111","author":"Vincenzi F.","year":"2016","unstructured":"Vincenzi F.; Ravani A.; Pasquini S.; Positive allosteric modulation of A adenosine receptors as a novel and promising therapeutic strategy for anxiety. Neuropharmacology 2016,111,283-292","journal-title":"Neuropharmacology"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"7216","DOI":"10.18632\/oncotarget.13802","volume":"8","author":"Vincenzi F.","year":"2017","unstructured":"Vincenzi F.; Borea P.A.; Varani K.; Anxiolytic properties of A1 adenosine receptor PAMs. Oncotarget 2017,8(5),7216-7217","journal-title":"Oncotarget"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nn.2562","volume":"13","author":"Goldman N.","year":"2010","unstructured":"Goldman N.; Chen M.; Fujita T.; Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci 2010,13(7),883-888","journal-title":"Nat Neurosci"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1038\/s41598-017-03542-x","volume":"7","author":"Fujita T.","year":"2017","unstructured":"Fujita T.; Feng C.; Takano T.; Presence of caffeine reversibly interferes with efficacy of acupuncture-induced analgesia. Sci Rep 2017,7(1),3397","journal-title":"Sci Rep"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"46663","DOI":"10.1038\/srep46663","volume":"7","author":"Yen L-T.","year":"2017","unstructured":"Yen L-T.; Hsieh C-L.; Hsu H-C.; Lin Y-W.; Targeting ASIC3 for relieving mice fibromyalgia pain: roles of electroacupuncture, opioid, and adenosine. Sci Rep 2017,7,46663","journal-title":"Sci Rep"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1096\/fj.04-1964fje","volume":"18","author":"McNamara N.","year":"2004","unstructured":"McNamara N.; Gallup M.; Khong A.; Adenosine up-regulation of the mucin gene, MUC2, in asthma. FASEB J 2004,18(14),1770-1772","journal-title":"FASEB J"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"H81","DOI":"10.1152\/ajpheart.01090.2009","volume":"299","author":"Ponnoth D.S.","year":"2010","unstructured":"Ponnoth D.S.; Nadeem A.; Tilley S.; Mustafa S.J.; Involvement of A1 adenosine receptors in altered vascular responses and inflammation in an allergic mouse model of asthma. Am J Physiol Heart Circ Physiol 2010,299(1),H81-H87","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/978-3-319-90808-3_18","author":"Pelleg A.","year":"2018","unstructured":"Pelleg A.; Polosa R.; Adenosine receptors in the lungs 2018,461-470","journal-title":"Adenosine receptors in the lungs"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"S446","DOI":"10.1038\/bjp.2008.22","volume":"153","author":"Brown R.A.","year":"2008","unstructured":"Brown R.A.; Spina D.; Page C.P.; Adenosine receptors and asthma. Br J Pharmacol 2008,153(Suppl. 1),S446-S456","journal-title":"Br J Pharmacol"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1472-8206.2005.00388.x","volume":"20","author":"Russo C.","year":"2006","unstructured":"Russo C.; Arcidiacono G.; Polosa R.; Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthma. Fundam Clin Pharmacol 2006,20(1),9-19","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1183\/09031936.00003707","volume":"31","author":"Brown R.A.","year":"2008","unstructured":"Brown R.A.; Clarke G.W.; Ledbetter C.L.; Elevated expression of adenosine A1 receptor in bronchial biopsy specimens from asthmatic subjects. Eur Respir J 2008,31(2),311-319","journal-title":"Eur Respir J"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pharmthera.2009.04.003","volume":"123","author":"Zhou Y.","year":"2009","unstructured":"Zhou Y.; Schneider D.J.; Blackburn M.R.; Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther 2009,123(1),105-116","journal-title":"Pharmacol Ther"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1517\/14728222.2013.795220","volume":"17","author":"Caruso M.","year":"2013","unstructured":"Caruso M.; Alamo A.; Crisafulli E.; Raciti C.; Fisichella A.; Polosa R.; Adenosine signaling pathways as potential therapeutic targets in respiratory disease. Expert Opin Ther Targets 2013,17(7),761-772","journal-title":"Expert Opin Ther Targets"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/sj.bjp.0706663","volume":"147","author":"Keir S.","year":"2006","unstructured":"Keir S.; Boswell-Smith V.; Spina D.; Page C.; Mechanism of adenosine-induced airways obstruction in allergic guinea pigs. Br J Pharmacol 2006,147(7),720-728","journal-title":"Br J Pharmacol"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11302-013-9397-9","volume":"10","author":"Burnstock G.","year":"2014","unstructured":"Burnstock G.; Purinergic signalling in the gastrointestinal tract and related organs in health and disease. Purinergic Signal 2014,10(1),3-50","journal-title":"Purinergic Signal"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.pharmthera.2008.08.010","volume":"120","author":"Antonioli L.","year":"2008","unstructured":"Antonioli L.; Fornai M.; Colucci R.; Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol Ther 2008,120(3),233-253","journal-title":"Pharmacol Ther"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1254\/jjp.68.119","volume":"68","author":"Suzuki M.","year":"1995","unstructured":"Suzuki M.; Tomaru A.; Kishibayashi N.; Karasawa A.; Effects of the adenosine A1-receptor antagonist on defecation, small intestinal propulsion and gastric emptying in rats. Jpn J Pharmacol 1995,68(1),119-123","journal-title":"Jpn J Pharmacol"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0014-2999(02)02766-8","volume":"458","author":"Kadowaki M.","year":"2003","unstructured":"Kadowaki M.; Nagakura Y.; Tokita K.; Hanaoka K.; Tomoi M.; Adenosine A1 receptor blockade reverses experimental postoperative ileus in rat colon. Eur J Pharmacol 2003,458(1-2),197-200","journal-title":"Eur J Pharmacol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11302-007-9081-z","volume":"4","author":"Bornstein J.C.","year":"2008","unstructured":"Bornstein J.C.; Purinergic mechanisms in the control of gastrointestinal motility. Purinergic Signal 2008,4(3),197-212","journal-title":"Purinergic Signal"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejmech.2018.03.067","volume":"151","author":"Lambertucci C.","year":"2018","unstructured":"Lambertucci C.; Marucci G.; Dal Ben D.; New potent and selective A adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases. Eur J Med Chem 2018,151,199-213","journal-title":"Eur J Med Chem"},{"key":"ref=210","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.4049\/jimmunol.157.10.4634","volume":"157","author":"Hask\u00f3 G.","year":"1996","unstructured":"Hask\u00f3 G.; Szab\u00f3 C.; N\u00e9meth Z.H.; Kvetan V.; Pastores S.M.; Vizi E.S.; Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996,157(10),4634-4640","journal-title":"J Immunol"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1523\/JNEUROSCI.4271-03.2004","volume":"24","author":"Tsutsui S.","year":"2004","unstructured":"Tsutsui S.; Schnermann J.; Noorbakhsh F.; A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 2004,24(6),1521-1529","journal-title":"J Neurosci"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"G972","DOI":"10.1152\/ajpgi.00346.2004","volume":"288","author":"Ghanem E.","year":"2005","unstructured":"Ghanem E.; L\u00f6vdahl C.; Dar\u00e9 E.; Luminal adenosine stimulates chloride secretion through A1 receptor in mouse jejunum. Am J Physiol Gastrointest Liver Physiol 2005,288(5),G972-G977","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ejphar.2010.10.041","volume":"650","author":"Antonioli L.","year":"2011","unstructured":"Antonioli L.; Fornai M.; Colucci R.; Differential recruitment of high affinity A1 and A2A adenosine receptors in the control of colonic neuromuscular function in experimental colitis. Eur J Pharmacol 2011,650(2-3),639-649","journal-title":"Eur J Pharmacol"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/jcp.26073","volume":"233","author":"Bahreyni A.","year":"2018","unstructured":"Bahreyni A.; Samani S.S.; Khazaei M.; Ryzhikov M.; Avan A.; Hassanian S.M.; Therapeutic potentials of adenosine receptors agonists and antagonists in colitis; Current status and perspectives. J Cell Physiol 2018,233(4),2733-2740","journal-title":"J Cell Physiol"},{"key":"ref=215","first-page":"937","volume":"12","author":"Zhang M.","year":"2006","unstructured":"Zhang M.; Budak M.T.; Lu W.; Identification of the A3 adenosine receptor in rat retinal ganglion cells. Mol Vis 2006,12,937-948","journal-title":"Mol Vis"},{"key":"ref=216","first-page":"1139","volume":"124","author":"Wan W.J.","year":"2011","unstructured":"Wan W.J.; Cui D.M.; Yang X.; Expression of adenosine receptors in human retinal pigment epithelium cells in vitro. Chin Med J (Engl) 2011,124(8),1139-1144","journal-title":"Chin Med J (Engl)"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1089\/jop.2016.0090","volume":"32","author":"Jacobson K.A.","year":"2016","unstructured":"Jacobson K.A.; Civan M.M.; Ocular purine receptors as drug targets in the eye. J Ocul Pharmacol Ther 2016,32(8),534-547","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"8108","DOI":"10.1167\/iovs.15-17202","volume":"56","author":"Zhang S.","year":"2015","unstructured":"Zhang S.; Li H.; Li B.; Adenosine A1 receptors selectively modulate oxygen-induced retinopathy at the hyperoxic and hypoxic phases by distinct cellular mechanisms. Invest Ophthalmol Vis Sci 2015,56(13),8108-8119","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1471-4159.2012.07909.x","volume":"123","author":"Brito R.","year":"2012","unstructured":"Brito R.; Pereira M.R.; Paes-de-Carvalho R.; Calaza Kda C.; Expression of A1 adenosine receptors in the developing avian retina: in vivo modulation by A(2A) receptors and endogenous adenosine. J Neurochem 2012,123(2),239-249","journal-title":"J Neurochem"},{"key":"ref=220","first-page":"1837","volume":"42","author":"Crosson C.E.","year":"2001","unstructured":"Crosson C.E.; Intraocular pressure responses to the adenosine agonist cyclohexyladenosine: evidence for a dual mechanism of action. Invest Ophthalmol Vis Sci 2001,42(8),1837-1840","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.bjp.0704267","volume":"134","author":"Avila M.Y.","year":"2001","unstructured":"Avila M.Y.; Stone R.A.; Civan M.M.A.; (1)-, A(2A)- and A(3)-subtype adenosine receptors modulate intraocular pressure in the mouse. Br J Pharmacol 2001,134(2),241-245","journal-title":"Br J Pharmacol"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1124\/jpet.106.110981","volume":"320","author":"Husain S.","year":"2007","unstructured":"Husain S.; Shearer T.W.; Crosson C.E.; Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1\/2 activation in human trabecular meshwork cells. J Pharmacol Exp Ther 2007,320(1),258-265","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jcp.22715","volume":"227","author":"Li A.","year":"2012","unstructured":"Li A.; Leung C.T.; Peterson-Yantorno K.; Stamer W.D.; Mitchell C.H.; Civan M.M.; Mechanisms of ATP release by human trabecular meshwork cells, the enabling step in purinergic regulation of aqueous humor outflow. J Cell Physiol 2012,227(1),172-182","journal-title":"J Cell Physiol"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.bbagen.2013.01.005","volume":"1830","author":"Zhong Y.","year":"2013","unstructured":"Zhong Y.; Yang Z.; Huang W-C.; Luo X.; Adenosine, adenosine receptors and glaucoma: an updated overview. Biochim Biophys Acta 2013,1830,2882-2890","journal-title":"Biochim Biophys Acta"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.mam.2016.12.001","volume":"55","author":"Peleli M.","year":"2017","unstructured":"Peleli M.; Carlstrom M.; Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications. Mol Aspects Med 2017,55,62-74","journal-title":"Mol Aspects Med"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0140-6736(13)62219-9","volume":"383","author":"Tuomi T.","year":"2014","unstructured":"Tuomi T.; Santoro N.; Caprio S.; Cai M.; Weng J.; Groop L.; The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014,383(9922),1084-1094","journal-title":"Lancet"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrendo.2015.10","volume":"11","author":"Antonioli L.","year":"2015","unstructured":"Antonioli L.; Blandizzi C.; Cs\u00f3ka B.; Pacher P.; Hask\u00f3 G.; Adenosine signalling in diabetes mellitus-pathophysiology and therapeutic considerations. Nat Rev Endocrinol 2015,11(4),228-241","journal-title":"Nat Rev Endocrinol"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/jcph.9","volume":"53","author":"Staehr P.M.","year":"2013","unstructured":"Staehr P.M.; Dhalla A.K.; Zack J.; Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist. J Clin Pharmacol 2013,53(4),385-392","journal-title":"J Clin Pharmacol"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1007\/s00125-015-3570-3","volume":"58","author":"Yang T.","year":"2015","unstructured":"Yang T.; Gao X.; Sandberg M.; Abrogation of adenosine A1 receptor signalling improves metabolic regulation in mice by modulating oxidative stress and inflammatory responses. Diabetologia 2015,58(7),1610-1620","journal-title":"Diabetologia"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1172\/JCI37409","volume":"119","author":"Peng Z.","year":"2009","unstructured":"Peng Z.; Borea P.A.; Varani K.; Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest 2009,119(3),582-594","journal-title":"J Clin Invest"},{"key":"ref=231","first-page":"E271","volume":"274","author":"Xu B.","year":"1998","unstructured":"Xu B.; Berkich D.A.; Crist G.H.; LaNoue K.F.; A1 adenosine receptor antagonism improves glucose tolerance in Zucker rats. Am J Physiol 1998,274(2),E271-E279","journal-title":"Am J Physiol"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.3390\/ijms19123837","volume":"19","author":"Sek K.","year":"2018","unstructured":"Sek K.; M\u00f8lck C.; Stewart G.D.; Kats L.; Darcy P.K.; Beavis P.A.; Targeting adenosine receptor signaling in cancer immunotherapy. Int J Mol Sci 2018,19(12),3837","journal-title":"Int J Mol Sci"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/jcp.25873","volume":"233","author":"Kazemi M.H.","year":"2018","unstructured":"Kazemi M.H.; Raoofi Mohseni S.; Hojjat-Farsangi M.; Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. J Cell Physiol 2018,233(3),2032-2057","journal-title":"J Cell Physiol"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.bbamem.2010.09.020","volume":"1808","author":"Gessi S.","year":"2011","unstructured":"Gessi S.; Merighi S.; Sacchetto V.; Simioni C.; Borea P.A.; Adenosine receptors and cancer. Biochimica et Biophysica Acta (BBA)-. Biomembranes 2011,1808,1400-1412","journal-title":"Biomembranes"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1159\/000481557","volume":"43","author":"Zhou Y.","year":"2017","unstructured":"Zhou Y.; Tong L.; Chu X.; The adenosine A1 receptor antagonist DPCPX inhibits tumor progression via the ERK\/JNK pathway in renal cell carcinoma. Cell Physiol Biochem 2017,43(2),733-742","journal-title":"Cell Physiol Biochem"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/onc.2009.409","volume":"29","author":"Lin Z.","year":"2010","unstructured":"Lin Z.; Yin P.; Reierstad S.; Adenosine A1 receptor, a target and regulator of estrogen receptoralpha action, mediates the proliferative effects of estradiol in breast cancer. Oncogene 2010,29(8),1114-1122","journal-title":"Oncogene"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.4161\/cbt.4.12.2196","volume":"4","author":"Mirza A.","year":"2005","unstructured":"Mirza A.; Basso A.; Black S.; RNA interference targeting of A1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis. Cancer Biol Ther 2005,4(12),1355-1360","journal-title":"Cancer Biol Ther"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1006\/bbrc.1998.8714","volume":"246","author":"Woodhouse E.C.","year":"1998","unstructured":"Woodhouse E.C.; Amanatullah D.F.; Schetz J.A.; Liotta L.A.; Stracke M.L.; Clair T.; Adenosine receptor mediates motility in human melanoma cells. Biochem Biophys Res Commun 1998,246(3),888-894","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=239","first-page":"203","volume":"12","author":"Hosseinzadeh H.","year":"2008","unstructured":"Hosseinzadeh H.; Jaafari M.R.; Shamsara J.; Selective inhibitory effect of adenosine A1 receptor agonists on the proliferation of human tumor cell lines. Iran Biomed J 2008,12(4),203-208","journal-title":"Iran Biomed J"},{"key":"ref=240","first-page":"93","volume":"14","author":"D\u2019Ancona S.","year":"1994","unstructured":"D\u2019Ancona S.; Ragazzi E.; Fassina G.; Mazzo M.; Gusella M.; Berti T.; Effect of dipyridamole, 5\u2032-(N-ethyl)-carboxamidoadenosine and 1,3-dipropyl-8-(2-amino-4-chlorophenyl)-xanthine on LOVO cell growth and morphology. Anticancer Res 1994,14(1A),93-97","journal-title":"Anticancer Res"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1365-2184.1995.tb00053.x","volume":"28","author":"Shaban M.","year":"1995","unstructured":"Shaban M.; Smith R.A.; Stone T.W.; Purine suppression of proliferation of Sertoli-like TM4 cells in culture. Cell Prolif 1995,28(12),673-682","journal-title":"Cell Prolif"},{"key":"ref=242","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.487","volume":"5","author":"Daniele S.","year":"2014","unstructured":"Daniele S.; Zappelli E.; Natali L.; Martini C.; Trincavelli M.L.; Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy. Cell Death Dis 2014,5","journal-title":"Cell Death Dis"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.canlet.2009.09.011","volume":"290","author":"Saito M.","year":"2010","unstructured":"Saito M.; Yaguchi T.; Yasuda Y.; Nakano T.; Nishizaki T.; Adenosine suppresses CW2 human colonic cancer growth by inducing apoptosis via A(1) adenosine receptors. Cancer Lett 2010,290(2),211-215","journal-title":"Cancer Lett"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.neuro.2005.12.008","volume":"27","author":"Sai K.","year":"2006","unstructured":"Sai K.; Yang D.; Yamamoto H.; A(1) adenosine receptor signal and AMPK involving caspase-9\/-3 activation are responsible for adenosine-induced RCR-1 astrocytoma cell death. Neurotoxicology 2006,27(4),458-467","journal-title":"Neurotoxicology"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/173509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T09:09:44Z","timestamp":1695028184000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/173509\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":244,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2019,10,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190716100509","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}